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ABSTRAK 
 
Sindrom Gilbert berpunca daripada keabnormalan pada gen uridine 
diphosphate-glucuronosyltransferase 1A1 (UGT1A1) yang disebabkan oleh 
mutasi. Mutasi-mutasi ini berbeza bagi setiap populasi dan kebanyakannya 
menjadi faktor asas bagi jaundis di kalangan neonat. Objektif kajian ini adalah 
untuk menentukan frekuensi mutasi-mutasi berikut pada gen UGT1A1: 
A(TA)7TAA (penyebab yang lazim bagi sindrom Gilbert di kalangan orang-orang 
Kaukasia), G71R (penyebab utama pada populasi Jepun dan Taiwan) dan 
G493R (dijumpai pada wanita Melayu yang membawa mutasi homozigus bagi 
sindrom Crigler-Najjar jenis ke-2) di kalangan bayi - bayi Melayu di Kelantan 
yang mengalami hiperbilirubinemia dan juga di kalangan bayi - bayi normal 
sebagai kawalan serta membandingkan frekuensi mutasi-mutasi ini di antara 
kedua-dua kumpulan bayi tersebut. Analisis serpihan penyaringan gen 
(GeneScan) telah digunakan untuk mengesan varian A(TA)7TAA. Penyaringan 
mutasi kedua-dua G71R dan G493R telah dijalankan dengan menggunakan 
kromatografi cecair denaturasi berprestasi tinggi [Denaturing high performance 
liquid chromatography (DHPLC)]. Seramai 14 daripada 55 orang neonat 
dengan hiperbilirubinemia (25%) membawa mutasi A(TA)7TAA (10 heterozigus, 
4 homozigus). Seramai 7 daripada 50 kawalan (14%) membawa mutasi ini (6 
 xviii
heterozigus, 1 homozigus). Frekuensi-frekuensi alel bagi bayi hiperbilirubinemia 
dan kawalan adalah masing-masing 16% dan 8% (p = 0.20). Heterozigositi 
mutasi G71R adalah lebih kurang sama bagi kedua-dua kumpulan (5.5% bagi 
bayi hiperbilirubinemia dan 6% bagi bayi yang tidak mengalami 
hiperbilirubinemia; p = 0.61). Seorang neonat (1.8%) dari kumpulan 
hiperbilirubinemia dan tiada neonat dari kumpulan kawalan mengalami mutasi 
heterozigus bagi G493R (p = 0.476). Kesimpulannya, A(TA)7TAA lebih ketara 
daripada mutasi G71R dan G493R di dalam populasi Melayu di Kelantan. 
Walaupun frekuensi alel bagi mutasi A(TA)7TAA di dalam kumpulan 
hiperbilirubinemia adalah dua kali ganda daripada kumpulan bukan 
hiperbilirubinemia, namun perbezaannya adalah tidak signifikan secara statistik. 
 
Kata kunci: Jaundis neonatal; gen UGT1A1; sindrom Gilbert; kromatografi 
cecair denaturasi berprestasi tinggi; penyaringan gen 
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ABSTRACT 
 
Gilbert syndrome is caused by defects in the uridine diphosphate-
glucuronosyltransferase 1A1 (UGT1A1) gene. These mutations differ among 
different populations and many of them have been found to be genetic risk 
factors for the development of neonatal jaundice. The objectives of this study 
were to determine the frequencies of the following mutations in the UGT1A1 
gene: A(TA)7TAA (the most common cause of Gilbert syndrome in Caucasians), 
G71R (more common in the Japanese and Taiwanese populations) and G493R 
(described in a homozygous Malay woman with Crigler-Najjar syndrome type 2) 
in a group of Malay babies in Kelantan with hyperbilirubinaemia and a group of 
normal controls and to compare the frequencies of these mutations between 
these group. The GeneScan fragment analysis was used to detect the 
A(TA)7TAA variant. Mutation screening of both G71R and G493R was 
performed using denaturing high performance liquid chromatography (DHPLC). 
Fourteen out of 55 neonates with hyperbilirubinaemia (25%) carried the 
A(TA)7TAA mutation (10 heterozygous, 4 homozygous). Seven out of 50 
controls (14%) carried the mutation (6 heterozygous, 1 homozygous). The allelic 
frequencies for hyperbilirubinaemia and control patients were 16% and 8% 
respectively (p = 0.20). Heterozygosity for the G71R mutation was almost equal 
among both groups (5.5% for hyperbilirubinaemia patients and 6.0% for 
controls; p = 0.61). One subject (1.8%) in the hyperbilirubinaemia group and 
none of the controls were heterozygous for the G493R mutation (p = 0.476). In 
 xx
conclusion, the A(TA)7TAA seems more common than the G71R and G493R 
mutations in the Malay population in Kelantan. Even though the allelic 
frequency of the A(TA)7TAA mutation in the hyperbilirubinaemia group was 
twice that of the non hyperbilirubinaemia group, the difference did not reach 
statistical significance. 
 
Keywords: Neonatal jaundice; UGT1A1 gene; Gilbert syndrome; denaturing 
high performance liquid chromatography; GeneScan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
INTRODUCTION 
 
1.1 Background of the study 
 
Neonatal jaundice is a common phenomenon among newborn infants. In 
Malaysia most of the neonatal jaundice presents during the first week of life. 
Many babies develop only mild jaundice which is believed to be physiological. 
This physiological jaundice is thought to be due to an immaturity of the liver 
function in the newborn infant and due to the shorter life span of red blood cells 
carrying foetal haemoglobin. 
 
On the other hand, many babies develop more severe jaundice, putting them at 
risk of developing bilirubin encephalopathy and kernicterus (American Academy 
of Pediatrics Subcommittee on Hyperbilirubinemia, 2004). Many causes have 
been identified for this more severe jaundice. The best known causes include 
haemolysis (such as rhesus incompatibility, ABO incompatibility or glucose - 6 - 
phosphate dehydrogenase (G-6-PD) deficiency), liver dysfunction (such as 
sepsis, Crigler-Najjar syndrome or metabolic disorders) and conditions which 
increase the enterohepatic circulation of bilirubin (such as breast feeding 
jaundice). A more detailed overview of the causes of neonatal jaundice and 
their importance will be given under subheading 1.4. 
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It is well known that in many cases of moderate or severe neonatal jaundice, 
the routine screening for common causes (including screening for G-6-PD 
deficiency, blood grouping, direct Coombs test and full blood picture) does not 
identify any cause. If in these cases there is neither a history of poor breast 
feeding, these babies are often labelled as having excessive physiological 
jaundice or more correctly, idiopathic pathological jaundice (Van Rostenberghe 
et al., 2004). The term ‘idiopathic’ implies that the cause is unknown. Recent 
evidence in literature suggests that causal factors of this type of neonatal 
jaundice may be due to point mutations in exons or mutations in the promoter 
region of the uridine-diphosphate glucuronosyltransferase 1 (UGT1A1) gene. 
This gene encodes the enzyme responsible for the rate limiting step for the 
bilirubin excretion. A thorough literature review about these mutations will be 
presented under subheading 1.5 and 1.6. 
 
Furthermore it is becoming increasingly clear that haemolysis in G-6-PD 
deficiency (and also ABO incompatibility) tends to be very mild and there is not 
much difference between babies developing neonatal jaundice and those not 
developing neonatal jaundice (Jalloh et al., 2005, Kaplan et al., 2005). Only 
about 20% of babies with G-6-PD deficiency develop jaundice requiring 
phototherapy. So then, what is the determining factor of which baby will and will 
not develop jaundice? It has been shown in some populations that again point 
mutations or mutations in the promoter region of the UGT1A1 gene are very 
important associated factors (Kaplan et al., 1997). 
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In different populations, different mutations in the UGT1A1 gene have been 
identified and allelic frequencies of these mutations were very different 
depending on the population (Akaba et al., 1998). No population study had 
been conducted so far regarding these mutations in any South-East Asian 
population. Since these mutations may be one of the determining factors 
whether or not a baby with G-6-PD deficiency will develop severe jaundice, it 
was felt that it is important to know in the Malaysian population whether 
mutations in this gene are common and whether they are related to the 
occurrence of jaundice. 
 
That is the reason why this population study was undertaken in a Malay 
population in Kelantan to determine the frequency of three mutations in the 
UGT1A1 gene in a group of jaundiced babies and in a group of babies with non-
jaundiced as controls. The first mutation is the A(TA)7TAA mutation (also 
referred to as TATA box mutation) which is a mutation in the promoter region of 
the gene. This mutation is the major cause of Gilbert syndrome in Caucasians. 
The second mutation is the G71R mutation, a mutation in the first exon, which is 
common in the Taiwanese and Japanese populations. The third mutation 
studied is the G493R mutation which had been recently detected in a Malay 
family with Crigler-Najjar syndrome. 
 
Before going into greater detail on the clinical aspects of neonatal jaundice and 
its causes, it is essential to have a clear understanding of the bilirubin 
metabolism itself which is described as follows. 
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1.2 Bilirubin metabolism 
 
Bilirubin is the end product of heme catabolism. It may play a role through its 
antioxidative properties in inhibition of lipid peroxidation. Bilirubin formation 
occurs in mononuclear phagocytes of liver, spleen and bone marrow, previously 
known as the reticuloendothelial system (Bhagavan, 2002, Ratnavel and Ives, 
2005). In some conditions, bilirubin formation may occur in renal tubular 
epithelial cells, hepatocytes and macrophages. 
 
About 75% of bilirubin is produced through haemolysis and most of the other 
25% through ineffective erythropoiesis (Bhagavan, 2002, Shapiro, 2003). Minor 
contributions to the serum bilirubin are made by the breakdown of myoglobin 
and the cytochromes. About 34 to 35 mg of bilirubin is produced by the 
degradation of 1 g of haemoglobin (Thilo, 1999, Zaghloul and Schulze, 2001). 
One mg/dL of serum bilirubin is equivalent to 17.2 μmol/L of bilirubin (Thilo, 
1999). In normal human metabolism, about 250 to 400 mg of bilirubin is 
generated daily. 
 
When haemoglobin is broken down, the globin part is enzymatically hydrolysed 
into amino acids. On the other hand, heme part of the haemoglobin molecule is 
bound to the heme oxygenase (a microsomal enzyme) which oxidizes the α-
methane carbon of heme to α-hydroxyhemin.  Autoxidation to biliverdin (a blue-
green pigment) occurs in the presence of oxygen and in the process iron and 
carbon monoxide (CO) are released (Figures 1.1 and 1.2). The released CO 
binds strongly to haemoglobin to form carboxyhaemoglobin (CO-Hb). 
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Measurement of this CO-Hb can give a reliable estimate the heme turn over 
(Bhagavan, 2002). 
 
Biliverdin is converted to bilirubin which is catalyzed by biliverdin reductase in 
the presence of NADPH (Bhagavan, 2002). This lipid soluble bilirubin is bound 
in the serum to albumin. Bound bilirubin-albumin complex is transported to the 
liver and taken up by hepatocytes. In the liver, bilirubin is conjugated with two 
glucuronide molecules. This process is catalysed by the enzyme, uridyl 
diphosphoglucuronyl transferase (UDPGT) and is the rate limiting step of 
bilirubin excretion (Ives, 1997).  Then, the bilirubin diglucuronide is excreted via 
the bile to the intestine. In the intestine, bilirubin diglucuronide is metabolized to 
stercobilins by the gut flora and excreted in the stool (Ratnavel and Ives, 2005).  
 
However, bilirubin diglucuronide is cleaved by mucosal beta-glucuronidase in 
the absence of gut flora or if it stays for a prolonged time in the intestinal lumen. 
In this condition, bilirubin is reabsorbed through the portal system (the 
enterohepatic circulation). Free bilirubin is unconjugated bilirubin which is not 
bound to albumin. This bilirubin has a potential to cross the blood brain barrier 
and damage neurons (Thilo, 1999). A schematic summary of the bilirubin 
metabolism pathway is given in Figures 1.1 and 1.2. 
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Figure 1.1 Schematic summary of the bilirubin metabolism pathway 
 
 
 
 
 
 
 
 
Red blood cells
Broken down 
Haemoglobin
Heme 
BilirubinBlood 
Bound to albumin 
Liver 
Glucuronisation 
Bile Bowel 
Stools 
 7
 
Figure 1.2 Pathway for heme degradation (Voet et al., 2002) 
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1.3 Clinical aspects of neonatal jaundice 
 
Jaundice or icterus can be defined as a yellowish discoloration of skin and 
sclera. This phenomenon is an indication of excess bilirubin in the blood. 
Clinical jaundice appears when the bilirubin level reaches about 90 µmol/L.  
Initially jaundice tends to appear in the face alone but as the 
hyperbilirubinaemia gets worse, other areas of the body become yellow as well. 
Generally it is assumed that jaundice reaching the abdomen indicates that the 
bilirubin level is about 250 µmol/L. If the legs are jaundiced it means there is 
severe hyperbilirubinaemia.  
 
Hyperbilirubinaemia can be divided into two types depending on the conjugation 
of bilirubin to glucuronide molecules: i.e. unconjugated hyperbilirubinaemia and 
conjugated hyperbilirubinaemia. 
 
1.3.1 Unconjugated hyperbilirubinaemia (Indirect hyperbilirubinaemia) 
 
Unconjugated hyperbilirubinaemia is caused by bilirubin which is not yet 
conjugated with glucuronide molecules (Thilo, 1999). This is the most common 
type of hyperbilirubinaemia found in neonates and its causes are listed in Table 
1.1. In the next subheading the most important causes of neonatal jaundice will 
be elaborated on a bit further. In severe hyperbilirubinaemia, unconjugated 
bilirubin may cross the blood brain barrier and cause neurological problems 
(kernicterus and bilirubin encephalopathy), renal damage and death (Clarke et 
al., 1997). 
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Kernicterus means jaundice of the nuclei in the brain. It was described by 
Christian Georg Schmorl in 1904. This pathological phenomenon is associated 
with a clinical entity, bilirubin encephalopathy. It is caused by bilirubin toxicity to 
the basal ganglia and various brainstem nuclei (Ives, 1997, 2004). This bilirubin 
toxicity is significantly higher among Asian newborns than among Caucasians 
(Akaba et al., 1998). 
 
The clinical syndromes of bilirubin encephalopathy are divided into two types; 
acute bilirubin encephalopathy and chronic bilirubin encephalopathy. Acute 
bilirubin encephalopathy is associated with lethargy, poor feeding, fluctuating 
hypotonia and hypertonia, high pitched cry, retrocollis, opisthotonus, impairment 
of upward gaze, fever, seizures and eventually death (Thilo, 1999, Shapiro, 
2003). Chronic bilirubin encephalopathy is the sequel of the acute type. The 
clinical features of chronic bilirubin encephalopathy range from mild mental 
retardation and subtle cognitive disturbances to severe athetoid cerebral palsy, 
deafness and seizures.  
 
1.3.2 Conjugated hyperbilirubinaemia (Direct hyperbilirubinaemia) 
 
This is an elevation of the serum bilirubin which is conjugated with glucuronide 
molecules. This water-soluble bilirubin diglucuronide is ready for excretion in 
bile and may increase when cholestasis occurs (Thilo, 1999). Conjugated 
hyperbilirubinaemia more commonly occurs after the first week of life, especially 
when the unconjugated hyperbilirubinaemia has decreased. The causes and 
the risk factors for conjugated hyperbilirubinaemia are listed in Table 1.2. 
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Table 1.1 Risk Factors for Neonatal Unconjugated Hyperbilirubinaemia 
Modified from the Clinical Use of Paediatric Diagnostic Tests  
(Barness and Barness, 2003) 
 
Maternal Factors Race or ethnic group 
-Native American, Asian, Greek Islander 
 
Complications during pregnancy 
-ABO incompatibility, Rhesus incompatibility, Diabetes 
mellitus 
 
Use of oxytocin in hypotonic solutions during labour 
 
Breast feeding: Breast-milk contains a competitive 
inhibitor of hepatic uridine-diphosphate 
glucuronosyltransferase  
 
Perinatal Factors Birth trauma 
-Ecchymoses, Cephalohematoma 
 
Infection 
-Viral 
-Bacterial 
-Protozoal 
 
Neonatal Factors Prematurity 
Genetic factors 
Familial disorders of conjugation 
-Crigler-Najjar syndrome (I and II), Gilbert syndrome 
 
Enzymatic defects causing haemolysis 
-Glucose-6-phosphate dehydrogenase deficiency 
-Pyruvate kinase deficiency, Hexokinase deficiency 
-Congenital erythropoietic porphyria 
 
Erythrocyte structural defects causing haemolysis 
-Elliptocytosis, Spherocytosis 
 
Polycythaemia  
Drugs 
-Chloramphenicol, Benzyl alcohol 
-Streptomycin sulfate, Sulfisoxazole 
Low intake of breast-milk (increased enterohepatic 
circulation) 
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Table 1.2 Risk Factors for Neonatal Conjugated Hyperbilirubinaemia 
Modified from the Clinical Use of Paediatrics Diagnostic Test  
(Barness and Barness, 2003) 
 
 
Disorder          Supporting information 
 
Infection     Improves with treatment. 
 
Total parenteral nutrition   History of total parenteral nutrition 
 
Biliary atresia    Pale stools. 
 
α1-Antitrypsin deficiency      - 
 
 
Alagille syndrome      Characteristic facies congenital  
      abnormalities. 
 
Galactosemia    Cataracts.Urinary reducing substances 
      positive. 
      Hypoglycemia, abnormal clotting. 
 
Tyrosinemia type 1      Serum amino acids increased. 
      Aminoacidemia. 
      Hepatocellular disease. 
      Increased serum α-fetoprotein. 
 
Zellweger syndrome   Hypotonia. Dysmorphic features. 
      Neurologic dysfunction.   
 
Cystic fibrosis    Meconium ileus may occur. 
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1.4 Common causes of neonatal jaundice 
1.4.1 Physiological jaundice 
 
Physiological jaundice most commonly occurs on day 3 to day 5 of life and 
decreases the first week after birth. It is usually associated with mild to 
moderate jaundice believed to be caused by a variety of factors: cessation of 
bilirubin clearance of placenta, immaturity of hepatic enzymatic systems at birth 
which decreases the ability to conjugate bilirubin, decreased hepatic uptake of 
bilirubin, larger red cell volume, shortened erythrocyte life span of cells carrying 
foetal haemoglobin and increased enterohepatic circulation (Hintz et al., 2001). 
  
Physiological jaundice is the most common cause of neonatal jaundice. It tends 
to be more severe in Asian populations than in Caucasian and Black 
populations (Zaghloul and Schulze, 2001). Quite often however, the term is 
used incorrectly to denote severe cases of neonatal jaundice. If screening for 
common causes does not reveal any cause, neonatal jaundice tends to be 
labelled as excessive physiological jaundice. A better term for this severe 
jaundice might be idiopathic pathological jaundice (Van Rostenberghe et al., 
2004). 
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1.4.2 Pathological causes 
1.4.2.1 Haemolytic causes 
1.4.2.1(a) ABO incompatibility 
 
ABO incompatibility most commonly occurs when a baby with blood group A or 
B is born to a mother with type O blood group. In these cases antibodies made 
by the mother against the blood group antigens of the baby may cross the 
placenta and cause haemolysis. The presence of these maternal antibodies in 
the baby’s blood is tested through the direct Coombs test, using heterologous 
anti-immunoglobulin (Kaplan and Hammerman, 2003). The Coombs test 
however has a high false negativity rate that may be related to a relatively low 
expression of the blood group antigens on the red blood cells of the neonate or 
to relatively low titres of antibodies. If jaundice occurs in ABO incompatibility, it 
typically starts on day 1 after birth (Thilo, 1999). 
 
1.4.2.1(b) Rhesus incompatibility 
 
Rhesus incompatibility occurs when a Rhesus negative mother carries a 
Rhesus positive baby. This condition results in severe anaemia antenatally, 
causing hydrops fetalis. It is also called erythroblastosis fetalis (Thilo, 1999). 
 
1.4.2.1(c) Glucose-6-phosphate dehydrogenase deficiency 
 
The enzyme glucose-6-phosphate dehydrogenase (G-6-PD) deficiency can be 
found in every cell in our body. It is used to protect cells (especially red blood 
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cells) against oxidative damage. The glutathione which is oxidised is used for 
neutralisation of toxic agents such as hydrogen peroxide and organic 
peroxidases (Mehta et al., 2000). To maintain the process, oxidized glutathione 
is directly changed back to the reduced form using hydrogen ions from NADPH. 
NADPH is formed from nicotinamide adenine dinucleotide phosphate (NADP) 
and this process is catalyzed by G-6-PD. Therefore, NADPH formation is 
disturbed in G-6-PD deficiency and this leads to fragility of the red blood cells in 
the presence of oxidative stresses. This process is illustrated in Figure 1.3. 
Residual G-6-PD activity and additional antioxidant enzymes such as catalase 
prevent significant haemolysis under physiological conditions but under oxidant 
stress conditions, severe haemolysis may occur (Mehta et al., 2000, Kaplan and 
Hammerman, 2002). 
 
G-6-PD deficiency is a major cause of neonatal jaundice (Mehta et al., 2000) 
and is common in many developing countries with limited access to modern 
medical care. Half of the morbidity and mortality which is associated with 
neonatal jaundice may be caused by G-6-PD deficiency (Kaplan et al., 2001a). 
 
Classically it was believed that the neonatal jaundice in babies with G-6-PD 
deficiency is due to haemolysis. However in the majority of cases there is no 
identifiable oxidative stress and haemolysis has been found to be very mild and 
similar in G-6-PD deficient babies developing jaundice and those not developing 
jaundice (Jalloh et al., 2005). 
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Figure 1.3 Diagram for the regeneration of NADPH (reduced form) from NADP 
in the presence of G-6-PD enzyme. This is a part of the antioxidant defence 
mechanism. GSH: Reduced Glutathione; GSSG: Oxidized Glutathione (Kaplan 
and Hammerman, 2002). 
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The presence of other risk factors for jaundice in combination with G-6-PD 
deficiency may become the crucial factor determining whether or not a baby 
with G-6-PD deficiency gets jaundiced. Such factors may include a decrease in 
bilirubin conjugation that may be related to promoter polymorphism in the gene 
which controls the bilirubin conjugating enzyme UDP-glucuronosyltransferase 
(Kaplan et al., 2001b). These findings were also supported by other studies 
(Bosma et al., 1995, Beutler et al., 2002). 
 
Total serum bilirubin levels in G-6-PD deficient neonates rise gradually and 
eventually leading to jaundice. This gradual onset jaundice may cause the 
jaundice to be missed in babies discharged early from the postnatal ward. This 
is the reason that in Malaysia, all babies are screened and the G-6-PD deficient 
babies are monitored for 5 days in the ward, so phototherapy can be started 
early so as to prevent the need for exchange transfusion.  
 
1.4.2.1(d) Other causes of haemolysis 
 
Another common cause of haemolysis is the extravasation of blood due to birth 
trauma. Extravasated blood is rapidly broken down and may cause severe 
hyperbilirubinaemia. Other less common causes of haemolysis can be found in 
Table 1.1. 
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1.4.2.2 Non-haemolytic causes of neonatal jaundice 
 
The common causes of jaundice without haemolytic disorder can be classified 
as follows: 
a) Increase of bilirubin production which is related to polycythaemia and 
swallowed blood. 
b) Decrease of bilirubin clearance, which is caused by UDPGT deficiency, 
resulting in Crigler-Najjar and Gilbert syndrome. A more detailed 
literature review on its relation to neonatal jaundice will be given in 
section 1.5. Decreased bilirubin clearance is also seen in hypothyroidism 
and breast feeding which is associated with jaundice. 
c) Unknown or multiple pathogeneses include altitude, racial differences, 
prematurity and bowel obstruction.  
 
1.5  Clinical syndromes associated with mutations in the UGT1A1 gene 
 
Decreased bilirubin clearance is attributed to Crigler-Najjar and Gilbert 
syndrome, due to lack of UDPGT enzyme in the liver. 
 
1.5.1 Crigler-Najjar syndrome 
 
Defects of the UGT1A1 gene may occur in any of its five exons and contribute 
to Crigler-Najjar syndrome, either type I or II (Kadakol et al., 2000). Crigler-
Najjar syndrome type I is the severe form and was described by Crigler and 
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Najjar in 1952 as a potentially lethal hyperbilirubinaemia (serum bilirubin 20–50 
mg/dL) without liver disease or overt haemolysis (Crigler and Najjar, 1952). 
 
Crigler-Najjar syndrome type II is an intermediate form with moderate elevations 
of the level of bilirubin (7–20 mg/dL). It is also known as Arias syndrome as it 
was described by Arias in 1962. It is commonly caused by a severe, but 
incomplete lack of UGT1A1 activity in the liver (Seppen et al., 1994). 
 
1.5.2 Gilbert syndrome 
 
Gilbert syndrome was first described by Augustin Gilbert and Pierre Lereboullet 
in 1901. Patients with Gilbert syndrome commonly have mild and chronic 
unconjugated hyperbilirubinaemia with normal liver function and without overt 
haemolysis (Sugatani et al., 2002). It is an inherited disorder of bilirubin 
metabolism.  
 
Gilbert syndrome is considered to be a harmless disease, but it may be a risk 
factor for neonatal jaundice, especially in combination with haemolytic 
disorders, such as G-6-PD deficiency and ABO incompatibility (Sutomo et al., 
2002, Kaplan et al., 2001a, Beutler et al., 2002). There is still controversy 
whether Gilbert syndrome is inherited as a recessive or dominant trait. Schmid, 
(1995) assumed that it was inherited as an autosomal dominant trait while a 
study by Bosma et al., (1995) suggested an autosomal recessive trait. 
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There may be different degrees of severity of the enzyme defect depending on 
the particular mutation. Some mutations are known to cause Crigler-Najjar 
syndrome type II in the homozygous state and Gilbert syndrome in the 
heterozygous state (Koiwai et al., 1995). Phenobarbital treatment has been 
found to increase the enzyme activity resulting in a decrease in the serum 
bilirubin level (Black and Sherlock, 1970).  
 
The incidence of Gilbert syndrome in the general population is about 3% to 10% 
(Iyanagi et al., 1998, Yamamoto et al., 1998). Hsieh and colleagues found that 
the TATA box mutation and G71R underlies the molecular background of 
Gilbert syndrome in the Taiwanese population. 
 
Simultaneous occurrence of more than one mutations were also found in this 
population which resulted in higher level of bilirubin and caused a more severe 
form of Gilbert syndrome (Hsieh et al., 2001). Since the UGT1A1 gene is the 
focus of this study, a more in depth review on the UGT1A1 gene is presented 
below. Several genotypes associated with Gilbert syndrome are listed in Table 
1.3. 
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Table 1.3: Genotypes causing Gilbert syndrome (Bosma et al., 2003) 
 
Refer to attached file: Table 1.3 
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1.6 The UGT1A1 gene 
 
The Uridine-diphosphoglucuronate-glucuronosyltransferases (UGTs) belong to 
the enzyme group of glycosyltransferases. UGTs in mammals have been 
classified into three families, based on the sequence similarity and structure of 
the gene: the UGT1, UGT2 and UGT8 (Meech and Mackenzie, 1997, Kadakol 
et al., 2000). Within these families there are several isoforms. Only two isoforms 
in the UGT1A family (UGT1A1 and UGT1A4) have bilirubin as a substrate but in 
humans only UGT1A1 plays a significant role in bilirubin glucuronidation 
(Bosma et al., 1994).  
 
UGT1A1 is located on chromosome 2q37 (Kiang et al., 2005) as represented in 
Figure 1.4 and is the focus of the current study. It consists of 5 exons. Exons 2 
to 5 are common exons of other isoforms within the UGT1A group (UGT1A1-13) 
and exon 1 is a unique exon for UGT1A1 (Figure 1.5). The four common exons 
at 3’ end encode the carboxyterminal domain for all isoforms of UGT which bind 
to UDP-glucuronic acid. The unique exon for each isoform at 5’ end encodes 
the N-terminal domain for the enzyme which specifies the substrate for the 
isoform. At least 13 exons (for UGT1A1 until UGT1A13) are located upstream of 
exon 2 (Ritter et al., 1992, Mackenzie et al., 1997, Watchko et al., 2002). 
 
A decrease in enzyme activity caused by defects or lesions in the UGT1A1 
gene results in unconjugated hyperbilirubinaemia (Sutomo et al., 2002). Several 
mutations in UGT1A1 gene have been reported to be associated with Gilbert 
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syndrome (e.g. the TATA box mutation (A(TA)7TAA), G71R and P229G) (Hsieh 
et al., 2001). For the purpose of this study three mutations were studied.  
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Figure 1.4 Human chromosome 2 
 (http://www.ensembl.org/Homo sapiens/mapview?chr=2) 
p 
q 
Location of the 
UGT1A1 gene 
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Figure 1.5 Schematic diagram of the UDPGT1 gene (Watchko et al., 2002) 
 
a) The entire UGT1 gene complex (UGT1A1–UGT1A13) and exons 2–5 of 
the UGT1A1 gene 
b) The UGT1A1 gene which consists of a normal TATA box in the promoter 
region and exons 2-5 of the gene 
 
 
 
 
 
 
 
 
 
